These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38752556)

  • 1. Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling.
    Marathe DD; Jauslin PM; Jan Kleijn H; De Miranda Silva C; Chain A; Abraham AK; Kauh EA; Liu Y; Perini RF; Alwis DP; Jain L
    J Clin Pharmacol; 2024 Oct; 64(10):1246-1258. PubMed ID: 38752556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
    N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
    Curry L; Soleimani M
    Future Oncol; 2024; 20(18):1251-1266. PubMed ID: 38639572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
    Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
    Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
    Marathe DD; Jauslin PM; Kleijn HJ; de Miranda Silva C; Chain A; Bateman T; Shaw PM; Abraham AK; Kauh EA; Liu Y; Perini RF; de Alwis DP; Jain L
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1499-1510. PubMed ID: 37596839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belzutifan: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
    Hasanov E; Jonasch E
    Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
    Iliopoulos O; Iversen AB; Narayan V; Maughan BL; Beckermann KE; Oudard S; Else T; Maranchie JK; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R; Jonasch E
    Lancet Oncol; 2024 Oct; 25(10):1325-1336. PubMed ID: 39284337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
    Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
    J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma.
    Rioja P; Rey-Cardenas M; De Velasco G
    Cancer Treat Rev; 2024 Sep; 129():102801. PubMed ID: 39032449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
    Wiley HE; Srinivasan R; Maranchie JK; Chhablani J; Iversen ABB; Kruse A; Jonasch E; Gombos DS; Else T; Demirci H; Maughan BL; Hartnett ME; Coleman HR; Fu W; Perini RF; Liu Y; Linehan WM; Chew EY;
    Ophthalmology; 2024 Nov; 131(11):1324-1332. PubMed ID: 38849055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belzutifan: A Narrative Drug Review.
    Visweswaran V; Pavithran K
    Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Peltola K; de Velasco G; Burotto M; Suarez C; Ghatalia P; Iacovelli R; Lam ET; Verzoni E; Gümüş M; Stadler WM; Kollmannsberger C; Melichar B; Venugopal B; Gross-Goupil M; Poprach A; De Santis M; Schutz FA; Park SH; Nosov DA; Porta C; Lee JL; Garcia-Del-Muro X; Biscaldi E; Manneh Kopp R; Oya M; He L; Wang A; Perini RF; Vickery D; Albiges L; Rini B;
    N Engl J Med; 2024 Aug; 391(8):710-721. PubMed ID: 39167807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
    Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
    Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological applications of belzutifan in von Hippel-Lindau disease.
    Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
    Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
    Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
    Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
    Choi WW; Boland JL; Kalola A; Lin J
    Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
    Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.